Arlen Wilcox

4PUBLICATIONS
19CO-AUTHORS
Biologically active moleculesPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Process control and simulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 22, 2024
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.

Daniel Vincent O'Hara, Abhinav Bassi, Arlen Wilcox

|Nov 17, 2022
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

Meg J Jardine, Sradha S Kotwal, Abhinav Bassi

|Apr 28, 2022
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial.

J M McGree, C Hockham, S Kotwal

|Aug 29, 2021
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial.

Carinna Hockham, Sradha Kotwal, Arlen Wilcox

Pageof 1

Frequent Collaborators

2 joint publications

Louise M Burrell

2 joint publications

Vinay Rathore

1 joint publications

Meg J Jardine

1 joint publications

Sradha S Kotwal